What do GLP-1 medications (Ozempic, Wegovy, Zepbound) do to your wearable recovery data?

What actually changes, metric by metric

This table summarizes the direction and rough magnitude reported in the studies below. Individual results vary — these are population averages, not predictions for any one person.

The study that actually measured this

The most direct evidence here comes from WHOOP's own performance science team, published in the American Journal of Physiology-Heart and Circulatory Physiology — a 12-week study comparing 66 WHOOP members who started a GLP-1 medication against 66 matched controls who didn't, tracked between November 2023 and April 2024. Ninety percent of the GLP-1 group lost at least 5% of body weight within 12 weeks, and the average member lost about 10%. Across the same period, resting heart rate rose by an average of 3 bpm and HRV fell by an average of 6ms relative to controls — a real, measurable autonomic shift, not sampling noise, though modest in absolute terms next to the weight change driving it.

A separate analysis of over 70,000 tracked activities from more than 300 GLP-1 users found a similar pattern at smaller scale: roughly a 1.1 bpm rise in minimum heart rate and a 1.8ms drop in nighttime HRV, both read as signs of somewhat reduced parasympathetic recovery during sleep. A systematic review and meta-analysis of randomized controlled trials — a higher evidence bar than observational wearable data — corroborates the direction: GLP-1 receptor agonists are associated with a heart rate increase in the 2-4 bpm range across non-diabetic adults with overweight or obesity, consistent across several individual drugs in the class.

Why a weight-loss drug moves your heart rate and HRV

The mechanism isn't primarily "the drug directly speeds up your heart" — it's an indirect chain through the autonomic nervous system. GLP-1 receptor agonists appear to reduce vagal (parasympathetic) tone and can increase sympathetic drive, both of which push resting heart rate up and HRV down independent of fitness or weight. Tirzepatide's dual action on GIP and GLP-1 receptors also causes measurable vasodilation in fat, gut, and skeletal muscle tissue; as blood vessels relax and peripheral resistance drops, the body's reflex response to keep blood pressure stable is a mild, compensatory increase in heart rate — the same "reflex tachycardia" seen with other vasodilating medications.

This is a distinct and separate cause from why an HRV baseline moves for other reasons — a device switch, illness, or a training-load change. Starting or changing a GLP-1 dose belongs on that same list of things that can genuinely shift a baseline, not something to troubleshoot as if your wearable is malfunctioning.

There's a rarer but medically notable end of this spectrum: published case reports describe tirzepatide worsening postural orthostatic tachycardia syndrome (POTS) in people who already had it — a distinctly different pattern from the ordinary 2-4 bpm shift, involving pronounced heart-rate spikes on standing plus dizziness or fainting. That's a clinical diagnosis territory, not a wearable-tracking one; if you already have POTS or a known autonomic condition, that's a conversation to have with your prescriber before or immediately after starting, not something to self-monitor via recovery score.

The muscle-mass side few wearables can see directly

Rapid weight loss on a GLP-1 medication comes from reduced caloric intake, and without a specific counter-stimulus, part of what the body sheds is muscle rather than fat — studies report roughly 10-15% or more of total weight lost as lean mass at higher doses, more pronounced in older adults and in people not doing resistance training. That number isn't unique to GLP-1s (typical calorie-restriction-only weight loss loses a comparable or even higher lean-mass share), but it matters here because rapid, drug-assisted loss makes it easy to lose weight fast without noticing the composition of what's coming off.

No consumer wearable measures lean body mass directly — see the lean body mass glossary entry for what it actually takes to measure this properly (DEXA scan, bioelectrical impedance, or similar). What a wearable can surface indirectly: workout performance declining faster than scale weight would explain, or strength dropping across weeks rather than staying stable as body weight falls. The research-backed countermeasure is resistance training two or more times per week combined with adequate protein intake — trials specifically designed to preserve lean mass during GLP-1 treatment show this combination substantially blunts the loss, in some cases close to eliminating it.

If you're getting periodic body-composition scans or bloodwork alongside a GLP-1 prescription, keeping those results alongside your wearable trends in one place — rather than in a folder of separate PDFs — makes the muscle-mass side of this much easier to actually track over months; Vita's health-report reader is built for exactly that photograph-a-lab-report-and-track-it-over-time use case.

What a dedicated wearable feature already does with this

This pattern is well-known enough that Oura built a specific feature around it: GLP-1 Insights lets you log your dose schedule and side effects alongside your Oura data, and will flag it directly if your readiness score dips in the day or two after a weekly injection — tying the biometric shift to the dosing calendar rather than leaving you to notice the correlation yourself. It's a genuinely useful piece of context-aware tracking if you're on Oura specifically. Vita doesn't offer dose-schedule logging today; what it does provide is the cross-source recovery score and trend view that makes an autonomic shift like this visible against your own personal baseline in the first place, whether your data comes from a WHOOP, an Apple Watch, or both merged together — the baseline-and-trend view is the part that matters for telling "expected dose-linked dip" apart from "something else going on," regardless of which device is doing the logging.

A practical way to track this over your first few months

1. Get a pre-medication baseline if you can. Two to four weeks of resting heart rate, HRV, and recovery data before starting gives you something real to compare against, rather than guessing at what "normal for you" used to look like.
2. Expect the first dip to land 1-2 days after a dose, especially early on. This mirrors the WHOOP and Oura data above; a same-pattern dip that recovers before the next dose is the expected shape, not a red flag.
3. Watch the 30-day trend for resting heart rate and HRV, not single days. A few bpm of average drift over 12 weeks is consistent with the published data; a heart rate that keeps climbing well past that window, or never comes back down between doses, is the pattern worth flagging.
4. Track strength and workout performance alongside the scale, not just weight. If strength is falling noticeably faster than a reasonable rate of fat loss would explain, that's your best wearable-adjacent signal for the muscle-mass question, since no consumer device measures it directly.
5. Bring the trend to your prescriber, not a diagnosis. "My resting heart rate has been running 8-10 bpm above my pre-medication baseline for six weeks" is useful clinical information. Self-diagnosing an autonomic condition from a wearable graph is not the goal here.

When to talk to a doctor rather than wait it out

Most of what's described above is a modest, temporary, dose-linked shift that doesn't require action beyond awareness. Treat it differently if you notice:

• A resting heart rate that keeps climbing well beyond the roughly 2-4 bpm population average and shows no sign of plateauing
• Heart-rate spikes specifically on standing up, along with dizziness, lightheadedness, or fainting — the POTS-adjacent pattern described above
• Chest discomfort, palpitations you can feel, or breathlessness at rest
• A recovery or readiness score that stays low continuously rather than dipping and recovering between doses
• Strength or performance dropping sharply alongside rapid weight loss, suggesting more muscle loss than the expected range

A wearable is well-suited to showing you that a pattern exists and roughly how large it is. It isn't suited to telling you whether that pattern is safe for you specifically, which depends on your cardiac history, other medications, and how your prescriber is monitoring the treatment — that judgment call belongs with them, not with a recovery score.